How to lower medical expenses for patients
“We want to make sure that if it is an efficacious medicine for that patient to consider using a generic formulation,” says Kelvin A. Moses, MD, PhD, FACS.
In this video, Kelvin A. Moses, MD, PhD, FACS, discusses the topics and advice from his presentation, “Financial and toxicity considerations when managing advanced PCa,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Moses is an associate professor of urology and fellowship director of urologic oncology at the Vanderbilt University Medical Center in Nashville, Tennessee.
Bundled payment program covers kidney stone care
July 22nd 2024"One day, we're going to have to move away from fee for service, so we'd be wise to try to navigate those waters ahead of time, so we're not left dealing with the aftermath when someone else has implemented it for us," says Ruchika Talwar, MD.
Lenvatinib plus pembrolizumab delays all organ tumor progression in advanced RCC
June 7th 2024“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.
Pembrolizumab plus platinum-based therapy shows safety, efficacy in penile cancer
June 4th 2024“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.
